WO2000074781A1 - Cosmetic depilation kit with photosensitizer - Google Patents

Cosmetic depilation kit with photosensitizer Download PDF

Info

Publication number
WO2000074781A1
WO2000074781A1 PCT/GB2000/002170 GB0002170W WO0074781A1 WO 2000074781 A1 WO2000074781 A1 WO 2000074781A1 GB 0002170 W GB0002170 W GB 0002170W WO 0074781 A1 WO0074781 A1 WO 0074781A1
Authority
WO
WIPO (PCT)
Prior art keywords
kit according
illumination
light
cosmetic kit
target zone
Prior art date
Application number
PCT/GB2000/002170
Other languages
French (fr)
Inventor
Michael Noel Kiernan
Robert Marc Clement
Original Assignee
Icn Photonics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Photonics Limited filed Critical Icn Photonics Limited
Priority to MXPA01012416A priority Critical patent/MXPA01012416A/en
Priority to AU50945/00A priority patent/AU5094500A/en
Priority to CA002376204A priority patent/CA2376204A1/en
Priority to BR0012108-8A priority patent/BR0012108A/en
Priority to EP00935403A priority patent/EP1183071A1/en
Priority to JP2001501311A priority patent/JP2003501168A/en
Priority to IL14681600A priority patent/IL146816A0/en
Priority to KR1020017015638A priority patent/KR20020023947A/en
Publication of WO2000074781A1 publication Critical patent/WO2000074781A1/en
Priority to NO20015808A priority patent/NO20015808L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A61B18/203—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser applying laser energy to the outside of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452—Skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452—Skin
    • A61B2018/00476—Hair follicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B2018/1807—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using light other than laser radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
    • A61N2005/0644—Handheld applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
    • A61N2005/0645—Applicators worn by the patient

Definitions

  • the present invention relates to a cosmetic depilation kit .
  • Laser hair removal is currently an effective and long term method for effecting cosmetic hair removal .
  • An exemplary laser depilation technique is disclosed m EP-A-0732895.
  • high intensity laser energy is directed towards the skin selectively heating hair surrounding the follicle leading to damage of the hair growth mechanism. If sufficient damage is induced, the hair follicle is effectively destroyed and the hair will not regrow.
  • This technique has disadvantages, one such being that scarring and pigmentary changes can occur. This is particularly the case where the individual being treated has dark skin and/or light hair.
  • Such techniques are also relatively slow, with the target zone needing to be covered by repeated laser pulses.
  • US-A-5669916 discloses a technique in which a hair is first plucked from a follicle before a photosensitive toxic material is directed along the path of the removed hair to the follicle. The toxic material is then activated by irradiation using laser.
  • the present invention provides a cosmetic kit for use in inhibiting hair growth, the kit comprising:
  • a marker substance including a photosensitive toxic material to tag subcutaneous hair growth cells of a target zone of skin
  • illumination apparatus for illuminating the skin in the target zone with light of a wavelength selected to effect preferential interaction with the hair growth cells tagged with the marker substance, resulting in a toxic effect inhibiting the hair growth capability of the tagged illuminated cells;
  • the marker substance is provided in a form comprising discrete portions of the photosensitive toxic material and a carrier material, the portions to be mixed prior to application to the target zone; and or,
  • the illumination apparatus includes an applicator configured to deliver non-laser light and/or configured to be placed against the target zone skin to deliver the illumination to the tagged hair growth cells .
  • the photosensitive toxic material is a material whose toxicity increases substantially upon exposure illumination of predetermined wavelength at sufficient energy delivered.
  • One such material is ALA (aminolevulinic acid) ; this and other materials are known in the art and described, for example in US-A-5669916.
  • the carrier material is beneficially a material easily absorbed into the skin an preferably comprises a moisturiser or absorbent emollient carrying the photosensitive toxic material in dissolved form or otherwise. It is important to maintain the carrier and the photosensitive toxic material separate until shortly prior to use in order to inhibit any adverse interaction between the materials prior to application to the skin of the target zone.
  • the portions of the photosensitive toxic material and the carrier material are dosed in a predetermined ratio. In one embodiment the proportion would be approximately 25% photosensitive toxic material to approximately 75% carrier material .
  • the kit beneficially includes a dispenser or a container- dispenser for dispensing the marker substance.
  • a container for the carrier material and or the photosensitive toxic material preferably affords light shielding of the photosensitive toxic material.
  • Mixing means is beneficially provided for mixing the photosensitive toxic material and the carrier material.
  • the mixing means preferably permits mixing of the photosensitive toxic material and the carrier material at a zone substantially sealed from the user.
  • a container for the photosensitive toxic material and the carrier material comprises respective sealed zones containing the photosensitive toxic material and the carrier material respectively, the zones being configured to be selectively breached or ruptured permitting mixing of the materials.
  • a mixing zone may be provided adjacent the breachable sealed zones, the mixing zone preferably communicating with a dispensing outlet.
  • the illumination apparatus preferably includes window means arranged to overlay the target zone skin, the illumination being directed via the window means.
  • the illumination apparatus includes an illumination applicator having a flexible structure arranged to conform to the target zone skin body part .
  • the illumination apparatus preferably includes:
  • an illumination applicator structure arranged to deliver illumination over a predetermined area
  • the illumination apparatus beneficially includes an illumination applicator structure having internal light reflecting walls and an associated light transmissive zone means through which reflected light is permitted to pass. This may be achieved, for example, where the applicator structure comprises one or more lengths of fibreoptic
  • the applicator structure comprises a plurality of lengths of fibre optic, the lengths being arranged to deliver light at different zones of the applicator structure
  • the marker substance is desirably preferentially absorbed by, or tagged to, hair growth cells in the target zone.
  • the excess proportion of the applied marker substance not absorbed by the hair growth cells is preferably metabolised and removed from the tissue by the normal action of the body.
  • the hair growth cells targeted for tagging are preferably so called 'stem' cells in the 'bulge' area of the follicle (adjacent the sebaceous gland) .
  • the marker substance is therefore selected to preferentially tag 'stem' cells.
  • the marker substance is preferably topically applied to the skin at the target zone. The marker substance penetrates into the skin to preferentially tag the target cells (typically by being preferentially absorbed) .
  • the marker substance preferably comprises a photo therapy drug such as for example 5-Aminolaevolinic Acid (5 -ALA) . Desirably the drug is provided in a topically administrable form such as a cream or the like.
  • the interaction of the illuminating light with the marking substance preferably results in the desired hair growth inhibition.
  • the interaction may be photochemical and/or photo-thermal in nature.
  • photochemical interaction light of a predetermined wavelength induces a chemical reaction between the marker substance and the tagged cells resulting in destruction of, or disabling of, the tagged cells.
  • photo-thermal interaction the incident light causes a temperature rise in the tagged cells to a degree sufficient to destroy or disable the tagged cell.
  • the wavelength of the illuminating light is preferably selected such that it is absorbed by the marker substance (or the tagged cell) .
  • the wavelength of the illuminating light is preferably substantially matched to the optical absorption characteristics of the marker substance.
  • the illuminating light is preferably substantially in the range 500nm-1000nm wavelength.
  • the light is preferably concentrated within a relatively narrow bandwidth within the range. This may be achieved by filtering of the light or use of light emitting apparatus arranged to emit a discrete wavelength (or band of wavelengths) .
  • the illuminating light includes on or more wavelengths substantially in the range 600nm- 650nm.
  • the illuminating light may, for example, be laser (including semiconductor laser), white light (preferably filtered), or LED light.
  • the intensity of the light is determined by the quantity of light required to produce the necessary interaction with the tagged cells. Generally however the intensity required will be substantially lower than the intensity required for prior art laser depilation techniques. This enables the technique to be more suitable for unsupervised 'Home' use.
  • the light may be pulsed or applied as continuous wave.
  • the light typically floods the target zone, which target zone is typically of an area in the range 0.5cm 2 -10cm 2 , more preferably lcm 2 -5cm 2 .
  • the energy applied per pulse to the target zone is preferably substantially in the range 40J or less (more preferably 25J or less) .
  • Figure 1 is a schematic representation of a mammalian hair follicle
  • Figure 2 is a schematic representation, similar to Figure 1, showing a first stage m application of the depilation technique
  • Figure 3 is a schematic representation similar to Figures 1 and 2, showing a subsequent stage m the technique
  • Figures 4 and 5 are schematic plan and side views respectively of a container-dispenser for the marker substance according to the invention.
  • Figures 6 and 7 show alternative general embodiments of illumination apparatus for inclusion m a kit according to the invention
  • Figure 8 is a schematic view of a laser diode illumination apparatus for inclusion m a kit according to the invention.
  • Figure 9 is a schematic view of LED illumination apparatus for inclusion m a kit according to the invention.
  • Figure 10 is a schematic view of 'white light' illumination apparatus for inclusion m a kit according to the invention.
  • Figure 11 is a schematic view of alternative 'white light' illumination apparatus for inclusion m a kit according to the invention.
  • Figure' 12 is a schematic view of a pad or patch applicator structure illumination apparatus for inclusion m a kit according to the invention
  • Figure 13 is a perspective view of the applicator pad or patch of figure 12;
  • Figure 14 is a sectional view of the fibreoptic used m the pad or patch of f gures 12 and 13 ;
  • Figure 15 is a schematic longitudinal section of the fibreoptic of figure 14.
  • FIG. 1 there is shown human hair follicle supporting a hair shaft 1 growing through the epidermis 2 and dermis 3 of mammalian skin tissue.
  • 'Ste ' cells 7 are present m the 'bulge' region 4 adjacent the sebaceous gland 5.
  • Stem cells have a relatively high turnover/life cycle and are responsible for instituting cyclical growth of the hair from the follicle .
  • a drug formulation including 5-Ammolaevol ⁇ n ⁇ c Acid is provided m a form for topical administration to the outer surface of the skin 6.
  • the drug 5-ALA is selected because it is selectively absorbed and retained m stem cells 7 when penetrating into the epidermal layer 3 (via epidermis 2) thereby effectively tagging the stem cells. Concentrations of the drug not absorbed m the stem cells 7 are metabolised and removed from the tissue by the normal' action of the body.
  • the target zone of the skin is directly illuminated from externally of the body by means of an illumination device 9 which supplies light of a preselected wavelength matched to a preselected characteristic absorption wavelength of the marker drug
  • the intensity of the light supplied, and duration of supply of the light is controlled such that either photochemical or photo-thermal interaction (or both) of the light with the tagged stem cells 7 causes disabling or destruction of the relevant stem cell 7 without disabling or destroying, substantially, the surrounding tissue material . This results m the tagged and disabled stem cell being inhibited from acting further to produce hair from the relevant follicle.
  • the technique by selectively marking/tagging and destroying stem cells preferentially (and the associated matching of the wavelength of the illuminating light) enables relatively low intensity light to be used, which may flood the target zone of the skm enabling a relatively large area of hair covered skin to be treated simultaneously.
  • the light from the illumination device 9 is pulsed to enable thermal relaxation of the skin to occur between consecutive pulses.
  • the energy supplied to the skin surface by the illuminating device 9 does not exceed 25J, before significant thermal relaxation of the skm is permitted.
  • the illuminating device may comprise laser, semiconductor laser, white light illumination device (typically with a filter) or an LED device.
  • the wavelength band width emitted where 5 -ALA is used as the marker is preferably substantially within the range 600nm - 650nm (which may be achieved by filtering if required) .
  • the low intensity nature of the light required to effect depilation using the technique according to the invention enables the technique to be relatively safe when compared to prior art laser hair removal techniques.
  • the drug formulation and illumination device may therefore be sold as a consumer kit for "home" use.
  • a "home use" kit for cosmetic depilation would typically comprise a power supply and lighting apparatus 10, 11 (see figures 6 and 7) for direct connection to mams power supply.
  • the apparatus 10, 11 either includes flexible electric connection to a light source 12 for application of illuminating radiation to the skin or, a "fixed" light source 13 and fibreoptic connection 14 to an applicator 16.
  • the other essential element of the kit is the market substance typically provided m a container 20 (see figures 4 and 5) which comprises a heat sealed plastics container/dispenser 20 having sealed chambers 21, 22, 23.
  • Chamber 21 contains the ALA material and chamber 23 carries the moisturiser/emollient carrier cream.
  • a manual pinch pressure causes seals 24, 25 to be ruptured and the respective materials to be urged from chambers 21, 23 into mixing chamber 22 where they become thoroughly, and intimately, mixed.
  • a cap 26 is subsequently broken from the end of nozzle 27 permitting the ALA and carrier mixture to be squeezed out of the container dispenser 20 under manual pressure.
  • the container dispenser 20 ensures that the correct proportions of ALA drug and carrier are mixed, and that mixing may be delayed until the point of application.
  • the illumination apparatus is applied to the sk and switched on.
  • the apparatus 110 m figure 8 includes a laser diode light source 125 contained within a protective casing 126 and mcludmg focussing optics 127 arranged to ensure the light is directed through a protective window 128.
  • the window 128 is held against the skm of the target zone to ensure correct delivery of the illuminating light to the target zone.
  • a 2D array of LEDs (light emitting diodes) 225 is utilised.
  • Focussing optics 227 ensure the light is directed through the protective window 228 m a similar manner to the arrangement of figure 8.
  • an electric filament "white light” source is used.
  • the source 325 is surrounded by a protective housing 326 including a shaped reflective surface 327 arranged to direct the light out of the housing via protective window 328.
  • a white light filament source 325 is once again used.
  • an internally reflecting light guide (such as a fibreoptic) is used.
  • the fibreoptic may be connected to a light applicator to be connected to the skm as will be described hereafter.
  • the apparatus of figure 12 shows an applicator pad or patch structure 426 which is typically flexible m nature, permitting the pad 426 to be conformed to the shape of the body part to which it is applied.
  • a flexible fibreoptic 435 which has a connector 436 arranged for mating connection to a corresponding connector 437 provided for the pad or patch structure.
  • the pad or patch structure 426 has an imbedded fibreoptic arrangement 440 including a series of spaced lengths of fibreoptic 441 extending across the pad or patch structure.
  • the fibreoptic path lengths form a serpentine arrangement, although a number of paths connected m parallel would also provide a convenient and workable arrangement.
  • the fibreoptic 440 includes .a reflective surface cladding 442 surrounding a core 443.
  • the surface cladding 442 ensures total internal reflection about the circumference of the fibreoptic except for an unclad window length 445 through which light can be emitted.
  • the pad or patch structure as shown m figures 12 to 15 provides a convenient arrangement that light can be distributed widely over a large area of skm surface m a convenient and safe manner.
  • Particular benefits of the invention are the arrangement of the carrier and the photosensitive toxic material in discrete separate package portions, easily mixable at the required time in order to ensure that detrimental effects of early mixing or incorrect dosage ratios are avoided.
  • the illumination apparatus configured to deliver non-laser light and/or configured to be placed against the target zone skm provide additional safety benefits and ensure that the skm is radiated to a consistent degree during treatment. This makes the kit particularly suitable for consumer/home use .

Abstract

A marker substance includes a photosensitive toxic material to tag subcutaneous hair growth cells of a target zone of skin. Illumination apparatus is used to illuminate the skin in the target zone with light of a wavelength selected to effect preferential interaction with the hair growth cells tagged with the marker substance, resulting in a toxic effect inhibiting the hair growth capability of the tagged illuminated cells; wherein. In the kit the marker substance may be provided in a form comprising discrete portions of the photosensitive toxic material and a carrier material, the portions to be mixed prior to application to the target zone. Additionally or alternatively, the illumination apparatus includes an applicator configured to deliver non-laser light and/or configured to be placed against the target zone skin to deliver the illumination to the tagged hair growth cells.

Description

COSMETIC DEPILATION KIT WITH PHOTOSENSITIZER
The present invention relates to a cosmetic depilation kit .
Laser hair removal is currently an effective and long term method for effecting cosmetic hair removal . An exemplary laser depilation technique is disclosed m EP-A-0732895. In such techniques, high intensity laser energy is directed towards the skin selectively heating hair surrounding the follicle leading to damage of the hair growth mechanism. If sufficient damage is induced, the hair follicle is effectively destroyed and the hair will not regrow. This technique has disadvantages, one such being that scarring and pigmentary changes can occur. This is particularly the case where the individual being treated has dark skin and/or light hair. Such techniques are also relatively slow, with the target zone needing to be covered by repeated laser pulses.
US-A-5669916 discloses a technique in which a hair is first plucked from a follicle before a photosensitive toxic material is directed along the path of the removed hair to the follicle. The toxic material is then activated by irradiation using laser.
An improved technique has now been devised. According to a first aspect, the present invention provides a cosmetic kit for use in inhibiting hair growth, the kit comprising:
a) a marker substance including a photosensitive toxic material to tag subcutaneous hair growth cells of a target zone of skin; and,
b) illumination apparatus for illuminating the skin in the target zone with light of a wavelength selected to effect preferential interaction with the hair growth cells tagged with the marker substance, resulting in a toxic effect inhibiting the hair growth capability of the tagged illuminated cells; wherein:
(i) the marker substance is provided in a form comprising discrete portions of the photosensitive toxic material and a carrier material, the portions to be mixed prior to application to the target zone; and or,
(ii) the illumination apparatus includes an applicator configured to deliver non-laser light and/or configured to be placed against the target zone skin to deliver the illumination to the tagged hair growth cells .
The photosensitive toxic material is a material whose toxicity increases substantially upon exposure illumination of predetermined wavelength at sufficient energy delivered. One such material is ALA (aminolevulinic acid) ; this and other materials are known in the art and described, for example in US-A-5669916.
The carrier material is beneficially a material easily absorbed into the skin an preferably comprises a moisturiser or absorbent emollient carrying the photosensitive toxic material in dissolved form or otherwise. It is important to maintain the carrier and the photosensitive toxic material separate until shortly prior to use in order to inhibit any adverse interaction between the materials prior to application to the skin of the target zone.
The portions of the photosensitive toxic material and the carrier material are dosed in a predetermined ratio. In one embodiment the proportion would be approximately 25% photosensitive toxic material to approximately 75% carrier material .
The kit beneficially includes a dispenser or a container- dispenser for dispensing the marker substance.
A container for the carrier material and or the photosensitive toxic material preferably affords light shielding of the photosensitive toxic material.
Mixing means is beneficially provided for mixing the photosensitive toxic material and the carrier material.
The mixing means preferably permits mixing of the photosensitive toxic material and the carrier material at a zone substantially sealed from the user.
Beneficially a container for the photosensitive toxic material and the carrier material comprises respective sealed zones containing the photosensitive toxic material and the carrier material respectively, the zones being configured to be selectively breached or ruptured permitting mixing of the materials. A mixing zone may be provided adjacent the breachable sealed zones, the mixing zone preferably communicating with a dispensing outlet.
The illumination apparatus preferably includes window means arranged to overlay the target zone skin, the illumination being directed via the window means.
In one embodiment, the illumination apparatus includes an illumination applicator having a flexible structure arranged to conform to the target zone skin body part .
The illumination apparatus preferably includes:
a) an illumination applicator structure arranged to deliver illumination over a predetermined area ;
b) a waveguide to connect with the illumination applicator; and,
c) a light source to direct light along the waveguide. The illumination apparatus beneficially includes an illumination applicator structure having internal light reflecting walls and an associated light transmissive zone means through which reflected light is permitted to pass. This may be achieved, for example, where the applicator structure comprises one or more lengths of fibreoptic
(preferably the applicator structure comprises a plurality of lengths of fibre optic, the lengths being arranged to deliver light at different zones of the applicator structure) .
The marker substance is desirably preferentially absorbed by, or tagged to, hair growth cells in the target zone. The excess proportion of the applied marker substance not absorbed by the hair growth cells is preferably metabolised and removed from the tissue by the normal action of the body. The technique according to the invention has been found to be effective even without the prior mechanical/physical depilation suggested in US-A- 5669916. Indeed such a step is discouraged due to the unnecessary trauma and pain it entails.
The hair growth cells targeted for tagging are preferably so called 'stem' cells in the 'bulge' area of the follicle (adjacent the sebaceous gland) . By effectively destroying or disabling the 'stem' cells once the hair has completed a growth cycle, a new hair cycle will be inhibited from starting, thereby preventing the follicle from functioning properly. The marker substance is therefore selected to preferentially tag 'stem' cells. The marker substance is preferably topically applied to the skin at the target zone. The marker substance penetrates into the skin to preferentially tag the target cells (typically by being preferentially absorbed) . The marker substance preferably comprises a photo therapy drug such as for example 5-Aminolaevolinic Acid (5 -ALA) . Desirably the drug is provided in a topically administrable form such as a cream or the like.
The interaction of the illuminating light with the marking substance preferably results in the desired hair growth inhibition. The interaction may be photochemical and/or photo-thermal in nature. For photochemical interaction, light of a predetermined wavelength induces a chemical reaction between the marker substance and the tagged cells resulting in destruction of, or disabling of, the tagged cells. For photo-thermal interaction, the incident light causes a temperature rise in the tagged cells to a degree sufficient to destroy or disable the tagged cell.
The wavelength of the illuminating light is preferably selected such that it is absorbed by the marker substance (or the tagged cell) . The wavelength of the illuminating light is preferably substantially matched to the optical absorption characteristics of the marker substance.
The illuminating light is preferably substantially in the range 500nm-1000nm wavelength. The light is preferably concentrated within a relatively narrow bandwidth within the range. This may be achieved by filtering of the light or use of light emitting apparatus arranged to emit a discrete wavelength (or band of wavelengths) . For example where 5 -ALA is used as the marker substance to tag the cells it is preferred that the illuminating light includes on or more wavelengths substantially in the range 600nm- 650nm.
The illuminating light may, for example, be laser (including semiconductor laser), white light (preferably filtered), or LED light.
The intensity of the light is determined by the quantity of light required to produce the necessary interaction with the tagged cells. Generally however the intensity required will be substantially lower than the intensity required for prior art laser depilation techniques. This enables the technique to be more suitable for unsupervised 'Home' use.
The light may be pulsed or applied as continuous wave. The light typically floods the target zone, which target zone is typically of an area in the range 0.5cm2-10cm2, more preferably lcm2-5cm2. The energy applied per pulse to the target zone is preferably substantially in the range 40J or less (more preferably 25J or less) .
The possibility of using lower intensity and non-laser light also enables a greater area target zone to be simultaneously illuminated, with reduced risk of skin burn. The technique is therefore safer and quicker. The invention will now be further described, m a specific embodiment, by way of example only and with reference to the accompanying drawings m which:
Figure 1 is a schematic representation of a mammalian hair follicle ;
Figure 2 is a schematic representation, similar to Figure 1, showing a first stage m application of the depilation technique;
Figure 3 is a schematic representation similar to Figures 1 and 2, showing a subsequent stage m the technique;
Figures 4 and 5 are schematic plan and side views respectively of a container-dispenser for the marker substance according to the invention;
Figures 6 and 7 show alternative general embodiments of illumination apparatus for inclusion m a kit according to the invention;
Figure 8 is a schematic view of a laser diode illumination apparatus for inclusion m a kit according to the invention;
Figure 9 is a schematic view of LED illumination apparatus for inclusion m a kit according to the invention;
Figure 10 is a schematic view of 'white light' illumination apparatus for inclusion m a kit according to the invention;
Figure 11 is a schematic view of alternative 'white light' illumination apparatus for inclusion m a kit according to the invention;
Figure' 12 is a schematic view of a pad or patch applicator structure illumination apparatus for inclusion m a kit according to the invention;
Figure 13 is a perspective view of the applicator pad or patch of figure 12;
Figure 14 is a sectional view of the fibreoptic used m the pad or patch of f gures 12 and 13 ; and
Figure 15 is a schematic longitudinal section of the fibreoptic of figure 14.
Referring to the drawings and initially to Figure 1, there is shown human hair follicle supporting a hair shaft 1 growing through the epidermis 2 and dermis 3 of mammalian skin tissue. 'Ste ' cells 7 are present m the 'bulge' region 4 adjacent the sebaceous gland 5. Stem cells have a relatively high turnover/life cycle and are responsible for instituting cyclical growth of the hair from the follicle .
In accordance with the invention, a drug formulation including 5-Ammolaevolιnιc Acid (5-ALA) is provided m a form for topical administration to the outer surface of the skin 6. The drug 5-ALA is selected because it is selectively absorbed and retained m stem cells 7 when penetrating into the epidermal layer 3 (via epidermis 2) thereby effectively tagging the stem cells. Concentrations of the drug not absorbed m the stem cells 7 are metabolised and removed from the tissue by the normal' action of the body.
After a predetermining period of time to allow the excess "marker" drug to be removed from the target zone tissue
(other than from the "tag" stem cells 7) , the target zone of the skin is directly illuminated from externally of the body by means of an illumination device 9 which supplies light of a preselected wavelength matched to a preselected characteristic absorption wavelength of the marker drug
(now tagging stem cells 7) .
The intensity of the light supplied, and duration of supply of the light, is controlled such that either photochemical or photo-thermal interaction (or both) of the light with the tagged stem cells 7 causes disabling or destruction of the relevant stem cell 7 without disabling or destroying, substantially, the surrounding tissue material . This results m the tagged and disabled stem cell being inhibited from acting further to produce hair from the relevant follicle.
The technique, by selectively marking/tagging and destroying stem cells preferentially (and the associated matching of the wavelength of the illuminating light) enables relatively low intensity light to be used, which may flood the target zone of the skm enabling a relatively large area of hair covered skin to be treated simultaneously. Typically, the light from the illumination device 9 is pulsed to enable thermal relaxation of the skin to occur between consecutive pulses. Typically, the energy supplied to the skin surface by the illuminating device 9 does not exceed 25J, before significant thermal relaxation of the skm is permitted.
The illuminating device may comprise laser, semiconductor laser, white light illumination device (typically with a filter) or an LED device. The wavelength band width emitted where 5 -ALA is used as the marker is preferably substantially within the range 600nm - 650nm (which may be achieved by filtering if required) .
The low intensity nature of the light required to effect depilation using the technique according to the invention, enables the technique to be relatively safe when compared to prior art laser hair removal techniques. The drug formulation and illumination device may therefore be sold as a consumer kit for "home" use.
Referring to figures 4 to 15 a "home use" kit for cosmetic depilation would typically comprise a power supply and lighting apparatus 10, 11 (see figures 6 and 7) for direct connection to mams power supply. The apparatus 10, 11 either includes flexible electric connection to a light source 12 for application of illuminating radiation to the skin or, a "fixed" light source 13 and fibreoptic connection 14 to an applicator 16.
The other essential element of the kit is the market substance typically provided m a container 20 (see figures 4 and 5) which comprises a heat sealed plastics container/dispenser 20 having sealed chambers 21, 22, 23.
Chamber 21 contains the ALA material and chamber 23 carries the moisturiser/emollient carrier cream. A manual pinch pressure causes seals 24, 25 to be ruptured and the respective materials to be urged from chambers 21, 23 into mixing chamber 22 where they become thoroughly, and intimately, mixed. A cap 26 is subsequently broken from the end of nozzle 27 permitting the ALA and carrier mixture to be squeezed out of the container dispenser 20 under manual pressure.
The container dispenser 20 ensures that the correct proportions of ALA drug and carrier are mixed, and that mixing may be delayed until the point of application.
Following application of the mixture topically to the target zone of skm, and subsequently waiting the required length of time to permit the concentration of ALA the non-target tissue to be reduced to the required low level, the illumination apparatus is applied to the sk and switched on.
Various forms of illuminating apparatus may be used. The apparatus 110 m figure 8 includes a laser diode light source 125 contained within a protective casing 126 and mcludmg focussing optics 127 arranged to ensure the light is directed through a protective window 128. Typically the window 128 is held against the skm of the target zone to ensure correct delivery of the illuminating light to the target zone.
In the' embodiment shown m figure 9 a 2D array of LEDs (light emitting diodes) 225 is utilised. Focussing optics 227 ensure the light is directed through the protective window 228 m a similar manner to the arrangement of figure 8.
In the apparatus shown m figure 10, an electric filament "white light" source is used. The source 325 is surrounded by a protective housing 326 including a shaped reflective surface 327 arranged to direct the light out of the housing via protective window 328.
In the embodiment shown figure 11, a white light filament source 325 is once again used. In this embodiment an internally reflecting light guide (such as a fibreoptic) is used. The fibreoptic may be connected to a light applicator to be connected to the skm as will be described hereafter.
The apparatus of figure 12 shows an applicator pad or patch structure 426 which is typically flexible m nature, permitting the pad 426 to be conformed to the shape of the body part to which it is applied. As shown m figures 13 to 15 additionally, light is directed to the pad or patch structure 426 by a flexible fibreoptic 435 which has a connector 436 arranged for mating connection to a corresponding connector 437 provided for the pad or patch structure. The pad or patch structure 426 has an imbedded fibreoptic arrangement 440 including a series of spaced lengths of fibreoptic 441 extending across the pad or patch structure. In the embodiment shown m figure 13, the fibreoptic path lengths form a serpentine arrangement, although a number of paths connected m parallel would also provide a convenient and workable arrangement. As shown in figure 14 the fibreoptic 440 includes .a reflective surface cladding 442 surrounding a core 443. The surface cladding 442 ensures total internal reflection about the circumference of the fibreoptic except for an unclad window length 445 through which light can be emitted.
The pad or patch structure as shown m figures 12 to 15 provides a convenient arrangement that light can be distributed widely over a large area of skm surface m a convenient and safe manner.
Particular benefits of the invention are the arrangement of the carrier and the photosensitive toxic material in discrete separate package portions, easily mixable at the required time in order to ensure that detrimental effects of early mixing or incorrect dosage ratios are avoided. The illumination apparatus configured to deliver non-laser light and/or configured to be placed against the target zone skm provide additional safety benefits and ensure that the skm is radiated to a consistent degree during treatment. This makes the kit particularly suitable for consumer/home use .

Claims

Cl aims :
1. A cosmetic kit for use m inhibiting hair growth, the kit comprising:
a) a marker substance including a photosensitive toxic material to tag subcutaneous hair growth cells of a target zone of skm; and,
b) illumination apparatus for illuminating the sk m the target zone with light of a wavelength selected to effect preferential interaction with the hair growth cells tagged with the marker substance, resulting m a toxic effect inhibiting the hair growth capability of the tagged illuminated cells; wherein:
d) the marker substance is provided m a form comprising discrete portions of the photosensitive toxic material and a carrier material, the portions to be mixed prior to application to the target zone; and or,
(ιι) the illumination apparatus includes an applicator configured to deliver non-laser light and/or configured to be placed against the target zone skm to deliver the illumination to the tagged hair growth cells.
2. A cosmetic kit according to claim 1, wherein the portions of the photosensitive toxic material and the carrier material are dosed m a predetermined ratio.
3. A cosmetic kit according to claim 1 or claim 2, including a dispenser for dispensing the marker substance .
4. A cosmetic kit according to any preceding claim, including a container for the carrier material and or the photosensitive toxic material .
5. A cosmetic kit according to claim 4, wherein the container affords shielding of the photosensitive toxic material.
6. A cosmetic kit according to any preceding claim, wherein mixing means is provided for mixing the photosensitive toxic material and the carrier material .
7. A cosmetic kit according to claim 6, wherein the mixing means permits mixing of the photosensitive toxic material and the carrier material at a zone substantially sealed from the user.
8. A cosmetic kit according to any preceding claim, wherein a container for the photosensitive toxic material and the carrier material comprises respective sealed zones containing the photosensitive toxic material and the carrier material respectively, the zones being configured to be selectively breached or ruptured permitting mixing of the materials.
9. A cosmetic kit according to claim 8, wherein a mixing zone is provided adjacent the breachable sealed zones, the mixing zone communicating with a dispensing outlet.
10. A cosmetic kit according to any preceding claim, wherein the illumination apparatus includes window means surface arranged to overlay the target zone skm, the illumination being directed via the window means .
11. A cosmetic kit according to any preceding claim, wherein the illumination apparatus includes an illumination applicator having a flexible structure arranged to conform to the target zone skm body part .
12. A cosmetic kit according to any preceding claim, wherein the apparatus includes:
(a) an illumination applicator structure arranged to deliver illumination over a large area;
(b) a waveguide to connect with the illumination applicator; and,
(c) a light source to direct light along the waveguide .
13. A cosmetic kit according to any preceding claim, wherein the apparatus includes an illumination applicator structure having internal light reflecting walls and an associated light transmissive zone means through which reflected light is permitted to pass.
14. A cosmetic kit according to claim 13, wherein the applicator structure comprises one or more lengths of fibreoptic.
15. A cosmetic kit according to claim 13 or claim 14, wherein the applicator structure comprises a plurality of lengths of fibre optic, the lengths being arranged to deliver light at different zones of the applicator.
PCT/GB2000/002170 1999-06-04 2000-06-05 Cosmetic depilation kit with photosensitizer WO2000074781A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MXPA01012416A MXPA01012416A (en) 1999-06-04 2000-06-05 Cosmetic depilation kit with photosensitizer.
AU50945/00A AU5094500A (en) 1999-06-04 2000-06-05 Cosmetic depilation kit with photosensitizer
CA002376204A CA2376204A1 (en) 1999-06-04 2000-06-05 Cosmetic depilation kit with photosensitizer
BR0012108-8A BR0012108A (en) 1999-06-04 2000-06-05 Set for cosmetic hair removal with photo-sensitizer
EP00935403A EP1183071A1 (en) 1999-06-04 2000-06-05 Cosmetic depilation kit with photosensitizer
JP2001501311A JP2003501168A (en) 1999-06-04 2000-06-05 Beauty hair removal kit with photosensitizer
IL14681600A IL146816A0 (en) 1999-06-04 2000-06-05 Cosmetic depilation kit with photosensitizer
KR1020017015638A KR20020023947A (en) 1999-06-04 2000-06-05 Cosmetic depilation kit with photosensitizer
NO20015808A NO20015808L (en) 1999-06-04 2001-11-28 Cosmetic hair removal equipment with photosensitive fabric

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9912998.3A GB9912998D0 (en) 1999-06-04 1999-06-04 Depilation
GB9912998.3 1999-06-04

Publications (1)

Publication Number Publication Date
WO2000074781A1 true WO2000074781A1 (en) 2000-12-14

Family

ID=10854730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002170 WO2000074781A1 (en) 1999-06-04 2000-06-05 Cosmetic depilation kit with photosensitizer

Country Status (13)

Country Link
EP (1) EP1183071A1 (en)
JP (1) JP2003501168A (en)
KR (1) KR20020023947A (en)
CN (1) CN1353620A (en)
AU (1) AU5094500A (en)
BR (1) BR0012108A (en)
CA (1) CA2376204A1 (en)
GB (1) GB9912998D0 (en)
IL (1) IL146816A0 (en)
MX (1) MXPA01012416A (en)
NO (1) NO20015808L (en)
WO (1) WO2000074781A1 (en)
ZA (1) ZA200109721B (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069825A2 (en) * 2001-03-02 2002-09-12 Palomar Medical Technologies, Inc. Apparatus and method for photocosmetic and photodermatological treatment
WO2002075307A1 (en) * 2001-03-15 2002-09-26 Ruprecht Keller Method for sample identification in a mammal as well as a kit for performing this method
US6723090B2 (en) 2001-07-02 2004-04-20 Palomar Medical Technologies, Inc. Fiber laser device for medical/cosmetic procedures
US8002768B1 (en) 1997-05-15 2011-08-23 Palomar Medical Technologies, Inc. Light energy delivery head
CN102499755A (en) * 2001-05-23 2012-06-20 帕洛玛医疗技术公司 Cooling system for photocosmetic device
US8328794B2 (en) 1996-12-02 2012-12-11 Palomar Medical Technologies, Inc. System for electromagnetic radiation dermatology and head for use therewith
US8388669B2 (en) 2007-03-30 2013-03-05 Panasonic Corporation Hair growth modulating method and modulation device thereof
WO2014195680A1 (en) * 2013-06-07 2014-12-11 Ambicare Health Limited Delivery mechanism for photodynamic therapy
US8915948B2 (en) 2002-06-19 2014-12-23 Palomar Medical Technologies, Llc Method and apparatus for photothermal treatment of tissue at depth
US9028536B2 (en) 2006-08-02 2015-05-12 Cynosure, Inc. Picosecond laser apparatus and methods for its operation and use
US9780518B2 (en) 2012-04-18 2017-10-03 Cynosure, Inc. Picosecond laser apparatus and methods for treating target tissues with same
US9919168B2 (en) 2009-07-23 2018-03-20 Palomar Medical Technologies, Inc. Method for improvement of cellulite appearance
US10245107B2 (en) 2013-03-15 2019-04-02 Cynosure, Inc. Picosecond optical radiation systems and methods of use
US10434324B2 (en) 2005-04-22 2019-10-08 Cynosure, Llc Methods and systems for laser treatment using non-uniform output beam
US10705073B2 (en) 2014-06-18 2020-07-07 Ruprecht Keller Method for identifying of a biological sample of a mammal, composition for use in this method and kit for performance of this method
US11418000B2 (en) 2018-02-26 2022-08-16 Cynosure, Llc Q-switched cavity dumped sub-nanosecond laser
US11894119B2 (en) 2019-07-04 2024-02-06 Ruma Gmbh Location-independent ingestion control

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458257B1 (en) 1999-02-09 2002-10-01 Lynntech International Ltd Microorganism control of point-of-use potable water sources
KR100817363B1 (en) * 2007-04-09 2008-03-26 김동호 An irradiator for laser treatment
CN107149726A (en) * 2017-06-21 2017-09-12 张健 Weak pulse washes life cosmetology depilator off

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3736933A (en) * 1970-12-02 1973-06-05 B Szabo Burstable seamed hypodermic applicators
US4093067A (en) * 1976-11-08 1978-06-06 John P. Glass Mixing package
WO1995007077A1 (en) * 1993-09-10 1995-03-16 The Norwegian Radium Hospital Research Foundation Photochemotherapeutic compositions containing 5-aminolevulinic acid
US5474528A (en) * 1994-03-21 1995-12-12 Dusa Pharmaceuticals, Inc. Combination controller and patch for the photodynamic therapy of dermal lesion
US5519534A (en) * 1994-05-25 1996-05-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irradiance attachment for an optical fiber to provide a uniform level of illumination across a plane
EP0732895A1 (en) 1993-12-08 1996-09-25 Sls Biophile Limited Depilation
WO1997032046A1 (en) * 1996-02-27 1997-09-04 New York Blood Center, Inc. Method and composition for hair removal
US5669916A (en) 1994-09-28 1997-09-23 The General Hospital Corporation Method of hair removal
US5835648A (en) * 1996-03-07 1998-11-10 Miravant Systems, Inc. Surface illuminator for photodynamic therapy
US5849027A (en) * 1996-09-04 1998-12-15 Mbg Technologies, Inc. Photodynamic therapy method and apparatus
WO1999010046A1 (en) * 1997-08-25 1999-03-04 Advanced Photodynamic Technologies, Inc. Treatment device for topical photodynamic therapy and method of making same

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3736933A (en) * 1970-12-02 1973-06-05 B Szabo Burstable seamed hypodermic applicators
US4093067A (en) * 1976-11-08 1978-06-06 John P. Glass Mixing package
WO1995007077A1 (en) * 1993-09-10 1995-03-16 The Norwegian Radium Hospital Research Foundation Photochemotherapeutic compositions containing 5-aminolevulinic acid
EP0732895A1 (en) 1993-12-08 1996-09-25 Sls Biophile Limited Depilation
US5474528A (en) * 1994-03-21 1995-12-12 Dusa Pharmaceuticals, Inc. Combination controller and patch for the photodynamic therapy of dermal lesion
US5519534A (en) * 1994-05-25 1996-05-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irradiance attachment for an optical fiber to provide a uniform level of illumination across a plane
US5669916A (en) 1994-09-28 1997-09-23 The General Hospital Corporation Method of hair removal
WO1997032046A1 (en) * 1996-02-27 1997-09-04 New York Blood Center, Inc. Method and composition for hair removal
US5835648A (en) * 1996-03-07 1998-11-10 Miravant Systems, Inc. Surface illuminator for photodynamic therapy
US5849027A (en) * 1996-09-04 1998-12-15 Mbg Technologies, Inc. Photodynamic therapy method and apparatus
WO1999010046A1 (en) * 1997-08-25 1999-03-04 Advanced Photodynamic Technologies, Inc. Treatment device for topical photodynamic therapy and method of making same

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8328794B2 (en) 1996-12-02 2012-12-11 Palomar Medical Technologies, Inc. System for electromagnetic radiation dermatology and head for use therewith
US8002768B1 (en) 1997-05-15 2011-08-23 Palomar Medical Technologies, Inc. Light energy delivery head
US8328796B2 (en) 1997-05-15 2012-12-11 Palomar Medical Technologies, Inc. Light energy delivery head
WO2002069825A2 (en) * 2001-03-02 2002-09-12 Palomar Medical Technologies, Inc. Apparatus and method for photocosmetic and photodermatological treatment
WO2002069825A3 (en) * 2001-03-02 2003-02-06 Palomar Medical Tech Inc Apparatus and method for photocosmetic and photodermatological treatment
USRE44859E1 (en) 2001-03-15 2014-04-22 Ruprecht Keller Method for sample identification in a mammal as well as a kit for performing this method
US7820444B2 (en) 2001-03-15 2010-10-26 Ruprecht Keller Method for sample identification in a mammal as well as a kit for performing this method
WO2002075307A1 (en) * 2001-03-15 2002-09-26 Ruprecht Keller Method for sample identification in a mammal as well as a kit for performing this method
CN102499755A (en) * 2001-05-23 2012-06-20 帕洛玛医疗技术公司 Cooling system for photocosmetic device
CN102499755B (en) * 2001-05-23 2014-11-12 帕洛玛医疗技术公司 Cooling system for photocosmetic device
US6723090B2 (en) 2001-07-02 2004-04-20 Palomar Medical Technologies, Inc. Fiber laser device for medical/cosmetic procedures
US10500413B2 (en) 2002-06-19 2019-12-10 Palomar Medical Technologies, Llc Method and apparatus for treatment of cutaneous and subcutaneous conditions
US10556123B2 (en) 2002-06-19 2020-02-11 Palomar Medical Technologies, Llc Method and apparatus for treatment of cutaneous and subcutaneous conditions
US8915948B2 (en) 2002-06-19 2014-12-23 Palomar Medical Technologies, Llc Method and apparatus for photothermal treatment of tissue at depth
US10434324B2 (en) 2005-04-22 2019-10-08 Cynosure, Llc Methods and systems for laser treatment using non-uniform output beam
US10966785B2 (en) 2006-08-02 2021-04-06 Cynosure, Llc Picosecond laser apparatus and methods for its operation and use
US9028536B2 (en) 2006-08-02 2015-05-12 Cynosure, Inc. Picosecond laser apparatus and methods for its operation and use
US10849687B2 (en) 2006-08-02 2020-12-01 Cynosure, Llc Picosecond laser apparatus and methods for its operation and use
US11712299B2 (en) 2006-08-02 2023-08-01 Cynosure, LLC. Picosecond laser apparatus and methods for its operation and use
US8388669B2 (en) 2007-03-30 2013-03-05 Panasonic Corporation Hair growth modulating method and modulation device thereof
US9919168B2 (en) 2009-07-23 2018-03-20 Palomar Medical Technologies, Inc. Method for improvement of cellulite appearance
US9780518B2 (en) 2012-04-18 2017-10-03 Cynosure, Inc. Picosecond laser apparatus and methods for treating target tissues with same
US11664637B2 (en) 2012-04-18 2023-05-30 Cynosure, Llc Picosecond laser apparatus and methods for treating target tissues with same
US10581217B2 (en) 2012-04-18 2020-03-03 Cynosure, Llc Picosecond laser apparatus and methods for treating target tissues with same
US10305244B2 (en) 2012-04-18 2019-05-28 Cynosure, Llc Picosecond laser apparatus and methods for treating target tissues with same
US11095087B2 (en) 2012-04-18 2021-08-17 Cynosure, Llc Picosecond laser apparatus and methods for treating target tissues with same
US11446086B2 (en) 2013-03-15 2022-09-20 Cynosure, Llc Picosecond optical radiation systems and methods of use
US10245107B2 (en) 2013-03-15 2019-04-02 Cynosure, Inc. Picosecond optical radiation systems and methods of use
US10765478B2 (en) 2013-03-15 2020-09-08 Cynosurce, Llc Picosecond optical radiation systems and methods of use
US10285757B2 (en) 2013-03-15 2019-05-14 Cynosure, Llc Picosecond optical radiation systems and methods of use
WO2014195680A1 (en) * 2013-06-07 2014-12-11 Ambicare Health Limited Delivery mechanism for photodynamic therapy
US10705073B2 (en) 2014-06-18 2020-07-07 Ruprecht Keller Method for identifying of a biological sample of a mammal, composition for use in this method and kit for performance of this method
US11418000B2 (en) 2018-02-26 2022-08-16 Cynosure, Llc Q-switched cavity dumped sub-nanosecond laser
US11791603B2 (en) 2018-02-26 2023-10-17 Cynosure, LLC. Q-switched cavity dumped sub-nanosecond laser
US11894119B2 (en) 2019-07-04 2024-02-06 Ruma Gmbh Location-independent ingestion control

Also Published As

Publication number Publication date
NO20015808D0 (en) 2001-11-28
IL146816A0 (en) 2002-07-25
MXPA01012416A (en) 2005-04-19
CN1353620A (en) 2002-06-12
CA2376204A1 (en) 2000-12-14
EP1183071A1 (en) 2002-03-06
NO20015808L (en) 2002-01-21
KR20020023947A (en) 2002-03-29
JP2003501168A (en) 2003-01-14
AU5094500A (en) 2000-12-28
BR0012108A (en) 2002-07-02
ZA200109721B (en) 2002-09-25
GB9912998D0 (en) 1999-08-04

Similar Documents

Publication Publication Date Title
WO2000074781A1 (en) Cosmetic depilation kit with photosensitizer
US7255691B2 (en) Chemiluminescent light source using visible light for biotherapy
CA2452408C (en) Method and apparatus for the photomodulation of living cells
Patil Overview of lasers
EP0841965B1 (en) Patch and controller for the photodynamic therapy of a dermal lesion
US8470010B2 (en) Systems and methods for treating superficial venous malformations like spider veins
US20030216795A1 (en) Apparatus and method for high energy photodynamic therapy of acne vulgaris, seborrhea and other skin disorders
US20060269580A1 (en) Treatment of skin with light and a benefit agent to mitigate acne
US20040225339A1 (en) Light treatments for acne and other disorders of follicles
AU2002320215A1 (en) Method and apparatus for the photomodulation of living cells
JP2008093469A (en) Alexandrite laser system for treatment of dermatological specimens
AU2003222006A1 (en) A device and method for treatment of external surfaces of a body utilizing a light-emitting container
KR20070054639A (en) Treatment of skin with light and a benefit agent
KR20040048888A (en) Method and apparatus for acne treatment
Whitehurst et al. Performance of a nonlaser light source for photodynamic therapy
Pokora Semiconductor lasers in selected medical applications

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808387.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 515687

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/012416

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2376204

Country of ref document: CA

Ref document number: 2376204

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2001 501311

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017015638

Country of ref document: KR

Ref document number: 50945/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000935403

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2001 2001132565

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000935403

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09980889

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020017015638

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000935403

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017015638

Country of ref document: KR